Abbott Laboratories (ABT)

37.90
NYSE : Health Care
Prev Close 37.60
Day Low/High 37.60 / 38.08
52 Wk Low/High 36.00 / 46.22
Avg Volume 8.40M
Exchange NYSE
Shares Outstanding 1.47B
Market Cap 55.36B
EPS 2.90
P/E Ratio 56.97
Div & Yield 1.04 (2.80%)

Latest News

Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches

Mad Money Lightning Round: Cramer Doesn't Want Health-Care Headaches

Horizon Pharma is a 'giant headache,' says Jim Cramer; Abbot Labs is OK long term.

Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week

Jim Cramer's Mad Money: Keep One Eye on Earnings, the Other on Politics Next Week

Holiday-shortened week holds a feast of earnings reports, says Jim Cramer.

European Union Regulators Said to Approve Abbott's St. Jude Acquisition

European Union Regulators Said to Approve Abbott's St. Jude Acquisition

European Union regulators are expected to approve Abbott Laboratories' $33 billion acquisition of St. Jude Medical.

Pfizer Finds Breaking Up Is Hard to Do

Pfizer Finds Breaking Up Is Hard to Do

Pfizer stock took a dive. Now what?

Abbott's Absorb™ Bioresorbable Stent Approved As The First Fully Dissolving Heart Stent In Japan

Abbott's Absorb™ Bioresorbable Stent Approved As The First Fully Dissolving Heart Stent In Japan

- Japan approval makes first-of-its-kind medical device available to people in Japan with coronary artery disease who prefer an alternative to a permanent metallic implant

Abbott Files Breach of Contract Suit Against Alere

Abbott Files Breach of Contract Suit Against Alere

Abbott wants more information from Alere, as promised under their pending $7.9 billion agreement.

A Great Place To Work, According To Science

A Great Place To Work, According To Science

TOP SCIENTIST: ABBOTT'S INNOVATION MISSION APPEALS TO 'HEARTS AND MINDS' OF SCIENTISTS

St. Jude Medical Shareholders Approve Merger With Abbott

St. Jude Medical Shareholders Approve Merger With Abbott

St. Jude Medical, Inc.

New Study: Babies Fed Infant Formula With 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies

New Study: Babies Fed Infant Formula With 2'-FL Human Milk Oligosaccharide+ Had Immune Response More Like Breastfed Babies

Levels of FIVE immune markers were nearly identical in breastfed babies and babies fed formula with 2'-FL Human milk oligosaccharide

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

Boston Scientific Remains Disciplined Buyer in Light of Large-scale Industry Consolidation

The medical devices company is likely to stick to small- to mid- sized M&A unless it finds itself the target.

Abbott Labs Is Likely to See Further Weakness

Abbott Labs Is Likely to See Further Weakness

Look for ABT's declining trend to continue a while longer.

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.

St. Jude Medical Still a Buy Despite Product Concerns

St. Jude Medical Still a Buy Despite Product Concerns

St. Jude shares deserve to be higher ahead of the merger with Abbott Labs. Here's why.

Abbott Labs Shares Climb on Better-Than-Expected Earnnigs

Abbott Labs Shares Climb on Better-Than-Expected Earnnigs

Shares of the medical-device giant were climbing after unveiling strong earnings.

Jim Cramer: Drug Stocks Feeling Political Pressure

Jim Cramer: Drug Stocks Feeling Political Pressure

Political pressure is weighing on drug and medical device stocks including Abbott Labs and St. Jude, says Jim Cramer.

Abbott CEO Is Unfazed by Muddy Waters' Attack on St. Jude

Abbott CEO Is Unfazed by Muddy Waters' Attack on St. Jude

Miles White also reiterated that Abbott Laboratories has no plans to divest of its diabetes business. He still believes in Alere over the long term.

St. Jude Spars With Muddy Waters After Earnings Miss

St. Jude Spars With Muddy Waters After Earnings Miss

The medical device maker responded to allegations that its devices could be hacked during its third quarter earnings call.

Abbott Labs (ABT) Stock Up on Q3 Earnings Beat

Abbott Labs (ABT) Stock Up on Q3 Earnings Beat

Abbott Labs ABT) on Wednesday morning posted earnings that were above analysts' expectations for the 2016 third quarter.

5 Things You Must Know Before the Market Opens Wednesday

5 Things You Must Know Before the Market Opens Wednesday

U.S. stock futures turn mixed; Yahoo!'s adjusted earnings top forecasts but revenue falls 14% in the third quarter; Intel guides to fourth-quarter revenue below consensus.

Abbott, St. Jude Float Antitrust Spinoff by FTC

Abbott, St. Jude Float Antitrust Spinoff by FTC

They plan to sell portions of their vascular closure and electrophysiology businesses to Japan's Terumo Corp. for $1.12 billion.

St. Jude Medical And Abbott To Sell Portion Of Vascular Closure And Electrophysiology Businesses To Terumo Corporation

St. Jude Medical And Abbott To Sell Portion Of Vascular Closure And Electrophysiology Businesses To Terumo Corporation

- The agreement is an important step toward completion of Abbott's acquisition of St. Jude Medical

What to Look for When Abbott Labs (ABT) Reports Q3 Earnings

What to Look for When Abbott Labs (ABT) Reports Q3 Earnings

On Wednesday, Abbott (ABT) is expected to post third-quarter earnings and revenue that are higher than a year ago.

Mad Money Looks at the Week Ahead: Earnings, Debates, the Fed and More

Mad Money Looks at the Week Ahead: Earnings, Debates, the Fed and More

Some of our favorite stocks will report earnings this week; here's a look at what else Jim Cramer is keeping an eye on.

Averting Trumpocalypse: How to Trade in the Week Ahead

Averting Trumpocalypse: How to Trade in the Week Ahead

Political anxiety, weak earnings and the dread of rising interest rates are weighing on markets. Here's how to protect your portfolio.

Jim Cramer's 'Mad Money' Recap: Here's My Game Plan for Next Week

Jim Cramer's 'Mad Money' Recap: Here's My Game Plan for Next Week

Cramer says his game plan is all about earnings, when the fundamentals control the market.

Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall

Illumina Leads Healthcare Selloff, Abbott and Zimmer Also Fall

Illumina fell 24% on news that it was cutting revenue guidance.